Oramed Pharmaceuticals (PRNewsFoto/Oramed Pharmaceuticals Inc)
Oramed has a sufficient cash balance to fund its clinical development timeline in the near term; several clinical milestones are scheduled for 2018 and 2019; stock target price remains at NIS 53.2.